Annika Dwucet

Medicine · Health Sciences

11h-index424citations38works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(13), Radiopharmaceutical Chemistry and Applications(12), HER2/EGFR in Cancer Research(10), Cancer therapeutics and mechanisms(6), Cell death mechanisms and regulation(5)

Publications36 total

Supplementary Figure 2 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure Legends from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 1 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Data from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 2 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 4 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure Legends from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 4 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 3 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 3 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 5 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 5 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Supplementary Figure 1 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
Data from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
2023Open Access
In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
Pharmaceuticals·2021· 21 citedOpen Access
ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
Frontiers in Cell and Developmental Biology·2021· 5 citedOpen Access
EXTH-68. DUAL METABOLIC REPROGRAMMING BY ONC201/TIC10 AND 2-DEOXYGLUCOSE HAS A STRONG ANTIPROLIFERATIVE EFFECT ON MEDULLOBLASTOMA CELLS
Neuro-Oncology·2021Open Access
CTNI-04. RECURRENT GLIOBLASTOMA LONG-TERM SURVIVORS TREATED WITH CUSP9v3
Neuro-Oncology·2021· 1 citedOpen Access
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
Cancers·2021· 21 citedOpen Access
A Pilot Clinical Study of CUSP9v3: Nine Repurposed Drugs Combined With Temozolomide for the Treatment of Recurrent Glioblastoma
2021Open Access
page 1 of 2Next →

Frequent Co-authors

Georg Karpel‐Massler(35), Marc‐Eric Halatsch(34), Richard E. Kast(31), Christian Rainer Wirtz(28), Klaus‐Michael Debatin(22), Lisa Nonnenmacher(18), Markus D. Siegelin(17), Mike‐Andrew Westhoff(17), Shaoxia Zhou(15), Max G. Bachem(15), M.-Andrew Westhoff(14), Tim Heiland(7), Michal Hlaváč(7), Maximilian Pruss(5), Katharina Zeiler(4), Benjamin Mayer(3), Oliver Zolk(3), Bernd Schmitz(3), Angelika Scheuerle(3), Ludwig Maier(3)